Advanced Search

 

Study ID Status Title Patient Level Data
207640 Completed Determination of the Sun Protection Factor of a Cosmetic Daily Defence Skin Cream
207644 Active, Not Recruiting Meta analysis of HPV-associated cases in efficacy studies according to baseline cytology and DNA status
207650 Not yet recruiting Qualitative Research in Patients with Diabetic Foot Ulcer
207654 Recruiting An open label parallel group study to investigate the optimum methodology for the use of LPS or GM-CSF as challenge agents on healthy participants by assessing inflammatory biomarkers in cantharidin-induced skin blisters, peripheral blood, and urine
207656 Not yet recruiting A Method Development Clinical Study Investigating the Efficacy of an Experimental Oral Rinse in Providing Long Term Relief from Dentinal Hypersensitivity
207660 Recruiting A phase III study (a placebo controlled, randomized, double-blind comparative study and an open-label, uncontrolled study) to evaluate the efficacy and safety of GSK1358820 in patients with post-stroke upper limb spasticity
207674 Completed A randomised, double-blind, parallel group study to evaluate the safety, tolerability and pharmacokinetics of a single dose of GSK2269557 administered via the ELLIPTA™ dry powder inhaler to healthy participants
207697 Not yet recruiting PGx7679: Exploratory Genetic Analysis for GSK2894512 for efficacy in psoriasis patients in 203120
207734 Not yet recruiting Post-Marketing Observational Study to Evaluate Safety Profile of Flixotide 50 μg pMDI Treatment in Chinese Subjects with Asthma aged 1-<4 years
207757 Not yet recruiting A long-term safety and efficacy follow-on study in participants with transfusion dependent beta-thalassemia who have previously received GSK2696277 (autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene) and completed the TIGET-BTHAL study
207781 Not yet recruiting Post-authorisation passive enhanced safety surveillance of seasonal influenza vaccines: Pilot study in England 2017/18
207782 Completed A Clinical Study to Assess the Cutaneous and Ocular Local Tolerance of Two Cosmetic Facial Cleansers in Healthy Females with Sensitive Skin Under Normal Conditions of Use
207872 Completed A Proof of Principal Study to Investigate the Stain Control of Two Stannous Fluoride Dentifrices
207877 Recruiting Meta-Analysis to evaluate the impact of exacerbations on Health-Related Quality of Life, FEV1, risk of further exacerbations, and mortality using data from GSK COPD observational studies and those for Fluticasone Propionate, Salmeterol/Fluticasone Propionate, Fluticasone Furoate/Vilanterol, and mepolizumab
207878 Completed Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with High Disease Activity (anti-dsDNA positive and low complement and SELENA-SLEDAI score >=10): A Pooled Analysis of the HGS1006-C1056 (BLISS-76) and HGS1006-C1057 (BLISS-52) Studies
207891 Not yet recruiting PGx7682 Exploratory Genetic Analysis for GSK2894512 for efficacy in atopic dermatitis patients in 203121
207926 Not yet recruiting PGx7680 Exploratory Meta-analysis of METRO (metformin response) and MetGen (Metformin response consortium)
207927 Not yet recruiting PGx7683_Exploratory PGx analysis for GSK1325760 (Ambrisentan) in 112565
207933 Active, not recruiting PGx7684: Confirmatory pharmacogenetic study investigating IL13 association with efficacy response to fluticasone furoate/vilanterol in asthma study 201378
207935 Not yet recruiting PGx7685:Exploratory PGx evaluation of adverse events observed in subjects treated with GSK3342830 in 204847 Part 2
207941 Not yet recruiting Meta-Analysis Plan for MID207941: A Study to Evaluate Risk Factors for Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in a COPD Population of Patients Treated with GW685698 + GW642444 (Fluticasone Furoate + Vilanterol); GW642444 (Vilanterol); CCI18781 (Fluticasone Propionate); GR33343 (Salmeterol); CCI18781+ GR33343 (Fluticasone Propionate + Salmeterol) and Placebo
208078 Not yet recruiting A Randomized, Examiner-blind, Proof of Principal Study to Investigate the Stain and Plaque Removal Capability of Two Experimental 5% Potassium Nitrate Dentifrices in Healthy Subjects with the Propensity for Extrinsic Dental Stain
208091 Not yet recruiting Meta-analysis of studies MEA115588 and 200862 of mepolizumab (SB240563) to evaluate changes in AM PEF in severe eosinophilic asthma (eTrack Study Identifier 208091)
208099 Not yet recruiting PGx7687: Exploratory Pharmacogenetic Study to Investigate Efficacy of SB252263 Tafenoquine on relapse of P Vivax Malaria in TAF112582 and TAF115654
208108/091 Completed A phase II, double-blind, randomized study to compare the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB/Hib2.5 to GSK Biologicals’ Tritanrix™-HepB/Hiberix™ when administered as a three-dose primary vaccination course to healthy infants at 6, 10 and 14 weeks of age. A dose of unconjugated Hib vaccine (plain PRP booster) will be administered at the age of 10 months to 50% of the subjects Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.